ArticleBreast cancer research : BCR2023
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
Article in Breast cancer research : BCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 12 citations in OpenAlex.
- Colour maps for representation of quantitative metrics in radiology: meaningful or misleading?Insights into imaging · 2026Review
- Association of PET/CT-Derived Metabolic Parameters with Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: An Analysis Across Molecular Subtypes.Diagnostics (Basel, Switzerland) · 2026Article
- Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics.Cancers · 2026Article
- Predictive Value of Dimensional and Functional MRI Parameters on Mid-Treatment MRI for Pathologic Complete Response in Breast Cancer.European journal of breast health · 2025Article
- Prognostic value of molecular and radiologic characteristics on dedicated breast [EJNMMI research · 2025Article
- Neoadjuvant Immunotherapy in Hormone Receptor-Positive Breast Cancer: From Tumor Microenvironment Reprogramming to Combination Therapy Strategies.International journal of molecular sciences · 2025Review
- Towards Standardized Language to Describe the Pathological Enhancement of the Nipple in NAC-Infiltrating Breast Tumors: A Retrospective Case Series Study.Diagnostics (Basel, Switzerland) · 2025Article
- Using [Cancers · 2025Article
- Breast cancer assessment under neoadjuvant systemic therapy using thoracic photon-counting detector computed tomography in prone position: a pilot study.European radiology experimental · 2025Article
- Distinguishing benign from malignant lesions with high [European journal of nuclear medicine and molecular imaging · 2025Article
- Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting.International journal of cancer · 2025Article
- Dynamic FDG PET/CT imaging: quantitative assessment, advantages and application in the diagnosis of malignant solid tumors.Frontiers in oncology · 2025Review
- Predicting histological grade in invasive ductal carcinoma of the breast: a radiomics-based machine learning model using DCE-MRI.Frontiers in oncology · 2025Article
- Repeated dynamic [European journal of nuclear medicine and molecular imaging · 2024Observational
- Image quality evaluation for a clinical organ-targeted PET camera.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeTo investigate combined MRI and
methodsPatients undergoing neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer were imaged at three timepoints (pre, mid, and post-NAC), prior to surgery. Imaging included diffusion-weighted and dynamic contrast-enhanced (DCE-) MRI and quantitative
resultsThirty-five patients with stage II/III invasive breast cancer were enrolled in the prospective study (median age: 43, range: 31-66 years, RCB 0/I: N = 11/35, 31%). Baseline imaging metrics were not significantly associated with pathologic response or RFS (p > 0.05). Greater mid-treatment decreases in peak PE, along with greater post-treatment decreases in several DCE-MRI and
conclusionMid-treatment changes in both PET and MRI measures were predictive of RCB status and RFS following NAC. Specifically, our results indicate a complementary relationship between DCE-MRI and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.